G1 Therapeutics, Inc. (GTHX)
NASDAQ: GTHX · IEX Real-Time Price · USD
3.300
-0.010 (-0.30%)
At close: May 31, 2024, 4:00 PM
3.351
+0.051 (1.55%)
After-hours: May 31, 2024, 7:45 PM EDT
G1 Therapeutics Revenue
G1 Therapeutics had revenue of $84.04M in the twelve months ending March 31, 2024, with 46.55% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $14.48M with 11.82% year-over-year growth. In the year 2023, G1 Therapeutics had annual revenue of $82.51M with 60.84% growth.
Revenue (ttm)
$84.04M
Revenue Growth
+46.55%
P/S Ratio
2.05
Revenue / Employee
$840,410
Employees
100
Market Cap
172.53M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 82.51M | 31.21M | 60.84% |
Dec 31, 2022 | 51.30M | 19.83M | 62.98% |
Dec 31, 2021 | 31.48M | -13.81M | -30.49% |
Dec 31, 2020 | 45.29M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 522.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGTHX News
- 4 days ago - Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) - GlobeNewsWire
- 9 days ago - G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting - GlobeNewsWire
- 10 days ago - G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit - GlobeNewsWire
- 10 days ago - G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses - GlobeNewsWire
- 4 weeks ago - G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 4 weeks ago - G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib - GlobeNewsWire
- 6 weeks ago - G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024 - GlobeNewsWire